Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS) : Prospective, national surveillance, United Kingdom and Ireland, 2020
Crown Copyright © 2021 Published by Elsevier Ltd..
BACKGROUND: Paediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS), first identified in April 2020, shares features of both Kawasaki disease (KD) and toxic shock syndrome (TSS). The surveillance describes the epidemiology and clinical characteristics of PIMS-TS in the United Kingdom and Ireland.
METHODS: Public Health England initiated prospective national surveillance of PIMS-TS through the British Paediatric Surveillance Unit. Paediatricians were contacted monthly to report PIMS-TS, KD and TSS cases electronically and complete a detailed clinical questionnaire. Cases with symptom onset between 01 March and 15 June 2020 were included.
FINDINGS: There were 216 cases with features of PIMS-TS alone, 13 with features of both PIMS-TS and KD, 28 with features of PIMS-TS and TSS and 11 with features of PIMS-TS, KD and TSS, with differences in age, ethnicity, clinical presentation and disease severity between the phenotypic groups. There was a strong geographical and temporal association between SARS-CoV-2 infection rates and PIMS-TS cases. Of those tested, 14.8% (39/264) children had a positive SARS-CoV-2 RT-PCR, and 63.6% (75/118) were positive for SARS-CoV-2 antibodies. In total 44·0% (118/268) required intensive care, which was more common in cases with a TSS phenotype. Three of five children with cardiac arrest had TSS phenotype. Three children (1·1%) died.
INTERPRETATION: The strong association between SARS-CoV-2 infection and PIMS-TS emphasises the importance of maintaining low community infection rates to reduce the risk of this rare but severe complication in children and adolescents. Close follow-up will be important to monitor long-term complications in children with PIMS-TS.
FUNDING: PHE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
The Lancet regional health. Europe - 3(2021) vom: 06. Apr., Seite 100075 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flood, Jessica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanepe.2021.100075 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32576784X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32576784X | ||
| 003 | DE-627 | ||
| 005 | 20240403232339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanepe.2021.100075 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM32576784X | ||
| 035 | |a (NLM)34027512 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flood, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS) |b Prospective, national surveillance, United Kingdom and Ireland, 2020 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Crown Copyright © 2021 Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Paediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS), first identified in April 2020, shares features of both Kawasaki disease (KD) and toxic shock syndrome (TSS). The surveillance describes the epidemiology and clinical characteristics of PIMS-TS in the United Kingdom and Ireland | ||
| 520 | |a METHODS: Public Health England initiated prospective national surveillance of PIMS-TS through the British Paediatric Surveillance Unit. Paediatricians were contacted monthly to report PIMS-TS, KD and TSS cases electronically and complete a detailed clinical questionnaire. Cases with symptom onset between 01 March and 15 June 2020 were included | ||
| 520 | |a FINDINGS: There were 216 cases with features of PIMS-TS alone, 13 with features of both PIMS-TS and KD, 28 with features of PIMS-TS and TSS and 11 with features of PIMS-TS, KD and TSS, with differences in age, ethnicity, clinical presentation and disease severity between the phenotypic groups. There was a strong geographical and temporal association between SARS-CoV-2 infection rates and PIMS-TS cases. Of those tested, 14.8% (39/264) children had a positive SARS-CoV-2 RT-PCR, and 63.6% (75/118) were positive for SARS-CoV-2 antibodies. In total 44·0% (118/268) required intensive care, which was more common in cases with a TSS phenotype. Three of five children with cardiac arrest had TSS phenotype. Three children (1·1%) died | ||
| 520 | |a INTERPRETATION: The strong association between SARS-CoV-2 infection and PIMS-TS emphasises the importance of maintaining low community infection rates to reduce the risk of this rare but severe complication in children and adolescents. Close follow-up will be important to monitor long-term complications in children with PIMS-TS | ||
| 520 | |a FUNDING: PHE | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Shingleton, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Brodie |e verfasserin |4 aut | |
| 700 | 1 | |a Amin-Chowdhury, Zahin |e verfasserin |4 aut | |
| 700 | 1 | |a Oligbu, Godwin |e verfasserin |4 aut | |
| 700 | 1 | |a Avis, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Lynn, Richard M |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Bharucha, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Pain, Clare E |e verfasserin |4 aut | |
| 700 | 1 | |a Jyothish, Deepthi |e verfasserin |4 aut | |
| 700 | 1 | |a Whittaker, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Dwarakanathan, Buvana |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Swann, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Semple, Malcolm G |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Mary E |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Christine E |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanan, Athimalaipet V |e verfasserin |4 aut | |
| 700 | 1 | |a Gent, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Ladhani, Shamez N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Europe |d 2021 |g 3(2021) vom: 06. Apr., Seite 100075 |w (DE-627)NLM323979734 |x 2666-7762 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2021 |g day:06 |g month:04 |g pages:100075 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanepe.2021.100075 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2021 |b 06 |c 04 |h 100075 | ||